Niagen Bioscience (NAGE) has drawn fresh attention after announcing a partnership with Truemed that lets qualified customers buy Tru Niagen using Health Savings Account and Flexible Spending Account funds on its direct website.

That HSA and FSA payment update arrives after a period of softer momentum, with a 90 day share price return of a 15.55% decline and a year to date share price return of a 0.96% decline, even as the three year total shareholder return sits at about 3.4x and the one year total shareholder return is 4.21%. This suggests longer term holders have seen far stronger outcomes than recent traders.

If this kind of health focused story has your attention, it may be worth broadening your watchlist with other healthcare stocks that are catching investors’ interest right now.

With shares recently under pressure, but longer term returns still far ahead of where they were three years ago, and with analyst and intrinsic estimates sitting above the US$6.19 close, is there still a buying opportunity here or is the market already pricing in future growth?

Most Popular Narrative: 61.4% Undervalued

Analysts following Niagen Bioscience see a fair value of US$16.04 per share, compared with the recent US$6.19 close, which sets up a wide valuation gap in their view.

Planned increases in R&D investments, alongside a potential investigational drug application for the use of NR in the treatment of ataxia telangiectasia, could lead to future earnings growth if successful pharmaceutical developments result in new, high-margin products.

Want to see what kind of revenue run rate and profit margin profile analysts think could support that gap, and what earnings multiple they are building in for years ahead? The full narrative lays out those projections in plain numbers.

Result: Fair Value of $16.04 (UNDERVALUED)

However, you still have to weigh risks such as intense competition in NAD boosters and ongoing regulatory or legal issues that could pressure margins and future earnings expectations.

Build Your Own Niagen Bioscience Narrative

If you see the story differently, or prefer to weigh the assumptions against the raw numbers yourself, you can build a custom view in a few minutes with Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Niagen Bioscience.

Looking for more investment ideas?

If Niagen Bioscience is on your radar, do not stop there. The broader market holds plenty of other ideas that could sharpen your portfolio thinking today.

• Scan for potential value ideas by checking out these 862 undervalued stocks based on cash flows, which is built around cash flow based opportunities that might deserve a closer look.
• Spot emerging themes in digital assets by reviewing these 80 cryptocurrency and blockchain stocks, which links equity markets with cryptocurrency and blockchain developments.
• Prioritise income focused opportunities by assessing these 12 dividend stocks with yields > 3%, which currently focuses on yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.